Sign In
Buy ARMP
$7.01
+0.140 (+2.04%)
At Close: Jun 23, 2026
New Strong Sell Stocks for May 8th
08:11am, Thursday, 08'th May 2025
ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.
Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia
New Strong Sell Stocks for April 28th
05:56am, Monday, 28'th Apr 2025
CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.
New Strong Sell Stocks for April 24th
07:25am, Thursday, 24'th Apr 2025
AMPY, CARS and CLB have been added to the Zacks Rank #5 (Strong Sell) List on April 24, 2025.
New Strong Sell Stocks for April 9th
06:25am, Wednesday, 09'th Apr 2025
CSIQ, ARMP and DAR have been added to the Zacks Rank #5 (Strong Sell) List on April 9, 2025.
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
05:56pm, Thursday, 20'th Mar 2025
LOS ANGELES , March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-p
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
05:08pm, Wednesday, 12'th Mar 2025
Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES , March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" o
LOS ANGELES , March 11, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-
Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -
LOS ANGELES , Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacterio
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
06:20pm, Wednesday, 13'th Nov 2024
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.31 per share a year ago.
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
04:05pm, Wednesday, 13'th Nov 2024
LOS ANGELES , Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriop
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025 LOS ANGELES , Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE Ameri
Armata Pharmaceuticals Announces Structural Biology Publication
07:00am, Wednesday, 30'th Oct 2024
Publication describes the structure of phage Pa193, a top candidate for inclusion into Armata's multi-phage anti-Pseudomonas clinical products LOS ANGELES , Oct. 30, 2024 /PRNewswire/ -- Armata Pharm
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Thursday, 12'th Sep 2024
Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
